NCT02848833View on ClinicalTrials.gov

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

CompletedOBSERVATIONAL
Enrollment

3,368

Participants

Timeline

Start Date

August 10, 2016

Primary Completion Date

April 17, 2020

Study Completion Date

April 17, 2020

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

JARDIANCE 10mg

T2DM with JARDIANCE 10mg

DRUG

JARDIANCE 25mg

MT2DM with JARDIANCE 25mgax

Trial Locations (1)

Unknown

Multiple Locations

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY